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’ INTRODUCTION
Apoptosis or programmed cell death is essential during
embryogenesis and cellular homeostasis and plays an important
role in the defense against pathogens. Defects in apoptotic
pathways contribute to a number of human diseases, such as
cancer and autoimmune or neurodegenerative diseases.1,2 Apop-
tosis is orchestrated by a group of intracellular cysteinyl aspartate
proteases called caspases,3 synthesized as inactive zymogens that
are activated through two major interconnected pathways:4,5 an
extrinsic pathway, activated by ligation of the so-called cell death
receptors, and an intrinsic pathway, caused by perturbation of the
mitochondria and regulated by the Bcl-2 family of proteins,
which is the focus of the present report.
To date, at least 20 Bcl-2 family members have been identiﬁed
in mammalian cells, including proteins that promote apoptosis
(hereafter referred as pro-apoptotic) and those that prevent it
(hereafter referred as anti-apoptotic). All these proteins are
characterized by exhibiting at least one of the four highly
conserved so-called Bcl-2 homology domains (hereafter referred
to as BH1-BH4), that are useful to classify these proteins into
three groups: (1) proteins, such as Bcl-2, Bcl-xL, Mcl-1, and Bﬂ-1,
all of which exhibit anticell death and conserve the four highly
conserved domains BH1-BH4; (2) proapoptotic multidomain
members, such as Bax, Bak, or Bok, which share sequence
homology in the BH1, BH2, and BH3 domains, and ﬁnally, (3)
the BH3-only proteins such as Bid, Bim, Bmf, Bik, Noxa, Puma,
Bad, and Hrk, which contain only a BH3 domain essential for
their killing function.610
The relative amount between pro- and anti-apoptotic proteins
determines the susceptibility of the cell to apoptosis. Indeed, in
many tumor cells Bcl-xL is overexpressed, impairing cell cap-
ability to undergo apoptosis and showing resistance to conven-
tional anticancer therapies. Therefore, inhibition of this protein
or reduction of its level modulates the drug resistance of tumor
cells by increasing their susceptibility to undergo apoptosis.
The anticell death activity of the anti-apoptotic proteins is due,
at least in part, to their dimerization with proapoptotic members of
the Bcl-2 family. Structural studies reveal that, in response to pro-
survival stimuli, anti-apoptotic proteins undergo a conformational
change that leads to the formation of a hydrophobic groove on their
surface where the amphipathic R-helical BH3 domain of the pro-
apoptotic protein binds.1114 By this process overexpressed pro-
survival proteins sequester pro-apoptotic ones compromising cell
capability to undergo apoptosis. Interestingly, the BH3 domain
fragments of pro-apoptotic proteins exhibit high aﬃnity for the pro-
survival proteins and play the role of antagonist of these proteins.
Indeed, binding of these peptides to the pro-survival proteins has
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survival members of this family of proteins is often associated with
the development of many types of cancer and confers resistance
against conventional therapeutic treatments. Accordingly, antag-
onism of its protective function has emerged as an encouraging
anticancer strategy. In the present work, we use a pharmacophore
for describing interaction between the BH3 domain of diﬀerent
pro-apoptoticmembers and the pro-survival protein Bcl-xL in order
to identify new lead compounds. In the strategy followed in the present work, the pharmacophore was derived from molecular
dynamics studies of diﬀerent Bcl-xL/BH3 complexes. This pharmacophore was later used as query for 3D database screening. Hits
obtained from the search were computationally assessed, and a subset proposed for in vitro testing. Two of the 15 compounds
assayed were found able to disrupt the Bcl-xL/Bak(BH3) complex with IC50 values in the lower micromolar range. Finally, docking
studies were performed to explore the binding mode of these compounds to Bcl-xL for further modiﬁcations.
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been shown to promote apoptosis in diﬀerent cell lines.1520
However, in order to surmount the diﬃculties associated to the
use of peptides as therapeutic agents, the design of small molecule
mimics of the BH3 domain of the pro-apoptotic members of the
Bcl-2 family can be considered as an appealing strategy for designing
new anticancer agents.
Following diﬀerent strategies, several groups have reported in
the last years the discovery of small-molecule antagonists of Bcl-2
or Bcl-xL (see Figure 1 and references therein). In this direction,
we report in the present work the results of a pharmacophore-
directed virtual screening approach for the discovery of small
molecules, antagonists of the Bcl-xL protein. Suitability of the
identiﬁed hits was assessed using the in-house docking program
DockDyn (DOCKing using DYNamic information), a docking
code based on the fulﬁlment of a recognition pharmacophore
derived from molecular dynamics (MD) simulations.36 Follow-
ing this procedure, 15 compounds were selected for in vitro
testing. Two of them competed with Bak(BH3) for binding to
Bcl-xL with IC50 values in the low micromolar range. Character-
ization of the binding mode of these compounds to Bcl-xL for
further optimization was performed through docking studies using
the Glide v4.037 module of the Maestro v8.5 suite of programs.38
’THEORETICAL CALCULATIONS
Pharmacophore Definition. In order to identify the stereo-
chemical features that characterize the binding of different hexade-
capeptides derived from the BH3 domain of pro-apoptotic proteins
(hereafter referred to as X(16BH3), where X represents Bak, Bax,
Bid, and Hrk) to Bcl-xL, MD simulations of different Bcl-xL/
X(16BH3) complexes were performed36 using the NMR structure
of the Bcl-xL /Bak (16BH3) complex (entry 1BXL of the Protein
Data Bank)11 as a template. Analysis of these trajectories permitted
us to identify four commonpharmacophoric points that characterize
the recognition features of the BH3 domains to Bcl-xL. These
chemical features, defined on the ligand, include: two hydrophobic
groups (HYD1 and HYD2) and two hydrogen-bond acceptors
(HBA1 and HBA2) as shown in Figure 2. To determine the spatial
arrangement of these pharmacophoric groups, each of them was
represented by a single point. For hydrophobic groups, the point
was located at the center of mass of the side chain. For hydrogen-
bond acceptor groups, the center of the oxygenoxygen carboxylic
distance was considered as pharmacophoric point. This reference
pharmacophore was defined using the maximum and the minimum
distance values adopted by each pair of pharmacophoric points
along the last 500 ps of the MD trajectory over the four Bcl-xL/
X(16BH3) complexes.
In Silico Database Screening and Selection. Hits were
identified according to their fulfilment of a pharmacophore query.
Different three-dimensional (3D) databases, including Available
Chemicals Directory (ACD, 266.812 compounds), National
Cancer Institute (NCI, 98.868 compounds), Maybridge (MB,
47.045 compounds), and Derwent World Drug (DWD, 48.405
compounds) were screened using the Catalyst package (Catalyst,
Accelrys Inc., San Diego, CA) with default parameters. Based on
the previously defined pharmacophore, four different queries were
Figure 1. Structures of some compounds reported as Bcl-2 and/or Bcl-xL inhibitors.
2132
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used for database searching: a four-point pharmacophore including
HYD1, HYD2, HBA1, and HBA2 and two three-point pharma-
cophores: HYD1, HYD2, and HBA1 and HYD1, HYD2, and
HBA2, labeled as phar4, phar31 and phar32, respectively.
Compounds matching at least one of the queries were stored
for further analysis.
Hits identiﬁed after screening the 3D databases were ﬁltered
according to their drug-likeness properties, and only those with a
molecular weight (MW) e800 Da were retained. Next, all
selected hits were further assessed using an in-house pharmaco-
phore-based docking program DockDyn.
Docking Studies.DockDyn is an in-house docking program36
based on pharmacophore fulfilment and steric features of the
binding site. DockDyn works in four steps: (1) assignment of
pharmacophoric features to each of the ligands to be docked; (2)
generation of ligand conformations; (3) discard of those con-
formations that do notmatch the pharmacophoric hypothesis; and
(4) docking and evaluation of the selected conformations into the
target binding site in order to evaluate their steric complementar-
ity. In the first step, DockDyn automatically assigns the pharma-
cophoric features to the ligand. These features include HBA,
hydrogen-bond donors (HBD), positive charges (Qþ), negative
charges (Q), hydrophobic moieties (HYD) and aromatic rings
(AR), although this list can be easily modified. Next, the program
identifies all the rotatable bonds of the ligand and generates new
conformations by rotation around these bonds. The rotational
angle increment depends on the number of total rotatable bonds
and on the type of bond. It is computed so that the number of
generated conformations remains equal or lower than a predeter-
mined value (default value is 2  105). Rotations are performed
using the quaternions formalism. Intramolecular clashes are taken
into account using the criteria that two atoms are in steric clash if
their distance is lower than the sum of their respective van der
Waals radii with some tolerance. At this point, the program checks
if the pharmacophoric features of any of the conformations
generated match the pharmacophoric hypothesis. If it is true, then
the program superimposes each of the pharmacophoric features of
a given conformation to the pharmacophoric hypothesis points
defined into the binding site of the protein. Superposition is done
by minimizing the root-mean-square standard deviation (RMSD)
between the pharmacophoric points of the ligand and those of the
reference pharmacophore. The RMSD value is used as a scoring
function to rank the compounds. Conformations with van der
Waals clashes were discarded. The criterion used is the same as
explained before for the intramolecular clashes but using another
tolerance factor in order to introduce some degree of protein
flexibility. If steric clash exists, then the program allows small
translations of the center of mass of the ligand into the binding site
of the protein to avoid it. In order to reduce the computational
cost, only residues of the protein with at least one atom within a
cutoff distance of 14 Å from the pharmacophoric reference points
are included in the calculation.
Glide. To avoid any possible bias introduced by our pharma-
cophore-directed program, docking studies were also carried out
with Glide,37 a general nonpharmacophore-dependent docking
program developed by Schr€odinger.38 Its choice was based on its
ability tomodel, through the Induced Fit Docking protocol,39 the
conformational changes induced in the protein by ligand binding.
This procedure works in four sequential steps: (1) use of a
softened van der Waals potential to dock the ligand into the rigid
receptor and to generate an initial ensemble of poses; (2) protein
sampling for each ligand pose by using Prime v1.6;40 (3)
redocking of the ligands into the best ranked induced fit
structures; and (4) scoring of the new ligand poses by using a
combination of the Prime energy and Glide XP score.
Initial coordinates of the Bcl-xL protein were taken from the
NMR complex Bcl-xL/Bak(7287) (PDB: 1BXL).11 Terminal
residues of the protein were manually charged. Bond orders and
protonation states of the protein were automatically adjusted by
using the Protein Preparation Wizard workﬂow included in the
Figure 2. Spatial rearrangement of the pharmacophoric groups found for the Bcl-xL protein. The model contains two hydrophobic groups (HYD1 and
HYD2) and two hydrogen-bond acceptors (HBA1 andHBA2). In the complex Bcl-xL/Bak(7287), the hydrophobic groups map the residues Ile81 and
Ile85 of the hexadecapeptide. The two hydrogen-bond acceptors match the residues Asp83 and Asp84, respectively.36
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Maestro v.8.5 software package. Ligand structures were manually
adjusted using the Builder module. Conformers and tautomers
were generated by using the LigPrep module included in the
Maestro package. The binding site of the Bcl-xL protein was
deﬁned on the Bak peptide, positioning the grid box used for the
docking stage on its center. Sizes for the inner and the outer
boxes were automatically deﬁned by default values. No residues
were mutated to alanine because there were no residues blocking
the binding site. In order to reduce steric clashes in the rigid
docking stage, a scaling factor of 0.5 in the van derWaals radii was
used for all atoms of the binding pocket. Prime protein reﬁne-
ment was carried out for the ﬁrst 20 poses obtained after initial
docking. It was performed for protein residues located within 5 Å
of the ligand. Finally, Glide redocking was carried out using the
XP default parameters on the protein structures having energies
in the range of 020 kcal/mol with respect to the lowest energy
value produced by Prime.
Energy Minimization. In order to adapt the docking structures
to the new force field calculations, the most probable complexes
producedbyGlidewereminimizedbyusing theAMBERv.9 program
package.41 The ff0342 and the GAFF force fields43 were used for the
protein and the ligands, respectively. All starting systemswere solvated
by adding a cubic box of explicit TIP3P water molecules44 with a
minimum distance between the protein and the edge of the box of
10 Å.Waters closer than 1.8 Å to any molecule or protein atom were
removed. Finally, the systems were neutralized with the necessary
counterions. Simulations were performed using periodic boundary
conditions with the long-range electrostatic interactions calculated by
means of the particlemesh Ewaldmethod.45 A cutoff distance of 10Å
was chosen to compute nonbonded interactions.
The minimizations were carried out in a multistep procedure.
In the three ﬁrst steps, 1000 steps of steepest descent followed by
4000 steps of conjugate gradient were done restraining the
protein backbone with a harmonic potential of force constant
of 50, 5, and 0.5 kcal/mol2 Å2, respectively. Finally, complexes
were minimized without any restriction until the root-mean-
square gradient of the potential energy was e0.001 kcal/mol.
Molecular Dynamics. Minimized complexes were used as
starting point for theMD simulations. TheMD simulations were
performed at a constant temperature of 300 K by coupling the
system to a thermal bath using Berendsen’s algorithm,46 as
implemented in AMBER9,41 with a time coupling constant of
0.2 ps. The SHAKE procedure47 was used to constrain all bonds
involving hydrogen atoms. The integration time was set to 2 fs
using the default value for the update of the nearest-neighbor list.
A cutoff of 9 Å for nonbonded interactions was used.
MD simulations started by heating the minimized structures to
300 K under constant volume and temperature conditions (N,V,T)
at a constant rate of 30 K/10 ps. Then, 100 ps of constant pressure
and temperature (N,P,T) allowed the system to reach the proper
density. Finally, a 6 ns dynamics calculation was performed in the
canonical ensemble (N,V,T) with a constant temperature of 300 K.
MM-PB/GBSA Approach. Binding free energies of the mini-
mized most-populated docked complexes were calculated using the
molecular mechanics PoissonBoltzmann/generalized Born surface
area (MM-PB/GBSA) approach48 implemented in theAMBERv.9.0
program package. This algorithm evaluates the binding free energy as
ΔGbinding ¼ ΔGgas þΔGsolv  TΔS
whereΔGgas is theMMinteraction energy betweenprotein and ligand
(sum of the nonbonded electrostatic (Coulombic), van der Waals
(Lennard-Jones), and internal energy contributions (bonds, angles
and dihedrals) in vacuo), ΔGsolv is the solvation free energy, and
TΔS is the conformational entropy change. ΔGsolv can be
expressed as the sum of an electrostatic (ΔGsolv,elec) component
and a nonpolar (ΔGnp) component:
ΔGsolv ¼ ΔGsolv, elec þΔGnp
The electrostatic contribution to the solvation free energy was
computed solving the PB equation or using the GB method.49 Both
methods assume that the nonpolar contribution is proportional to
the solvent accessible surface area (SASA). It is calculated asΔGnp=
γ SASAþ b, with γ = 0.00542 kcal/mol Å2 and b = 0.92 kcal/mol
for PB and γ = 0.0072 kcal/mol Å2 and b = 0 kcal/mol for
GB calculations, employing the Linear Combinations of Pairwise
Overlaps (LCPO) method.50 Values of the internal and external
dielectric constants were 1 and 80, respectively. Entropic contribu-
tions were neglected.
To estimate the contribution of each residue of the Bcl-xL
protein to the binding free energy, the MM-GBSA per residue
protocol51 was applied. This methodology describes not only the
interactions in vacuo but also adds the solvation contribution to
the ﬁnal binding free energy. In this approach all pairwise
interactions are equally distributed between the interacting atoms.
’EXPERIMENTAL SECTION
Inhibition Assays. Fluorescence polarization measurements
were made in a Victor2 V 1420 Multilabel HTS Counter. A 60 nM
solution of 50-60-carboxyfluorescein (CF) labeled peptide derived
from the BH3 domain of Bak (CF-Bak(BH3); CF-GQVG-
RQLAIIGKKINR-NH2;
52 λexc = 480 nm; λem = 535 nm) in buffer
A (total reaction volumewas 200μL)was titratedwith concentrated
Bcl-xL protein solutions in the presence and absence of
compounds.53 Data were recorded by using a Wallac 1420 Work-
station software.
β-Lactamase Assays. β-Lactamase assays were performed
using 2 nM enzyme. Compounds were preincubated with the
enzyme for 15 min at room temperature. After incubation,
200 μM of a β-lactamase-labile, chromogenic cephalosporin
reagent (CENTA), was added to the mixture. The reaction
was monitored by measuring the increase in absorbance at
405 nm produced by the hydrolysis of the β-lactam ring.
’RESULTS AND DISCUSSION
Virtual screening has been successfully used by diverse groups
to identify smallmolecule antagonists of the Bcl-xL or Bcl-2 proteins.
Wang and co-workers used a virtual screening process to identify
compound HA14-1 (Figure 1), a nonpeptidic and cell permeable
antagonist of Bcl-2.17 High-throughput virtual screening was also
used by Petros and co-workers to identify new antagonists of the
Bcl-2 protein.13 One of them inhibits cell growth with an IC50 of
4 μM and induces apoptosis in cancer cells. In both studies, the 3D
structure of the Bcl-2 protein was obtained by homology modeling.
The program DOCK was then used to screen a molecular database
against the binding site of the protein. Recently, a virtual screening
using a receptor-based pharmacophore has been used to discover a
new low-micromolar Bcl-2 inhibitor.54
The novelty of the results reported in the present work regards
the use of an average pharmacophore derived fromMD studies of
the Bcl-xL/X(16BH3) complexes, not only as a query to screen
several molecular databases but also for docking the selected
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compounds by matching them to this averaged pharmacophore
model positioned into the binding site of the protein.
As has been explained in the Theoretical Calculations Section,
three diﬀerent queries phar4, phar31, and phar32 based on the
averaged pharmacophore (Figure 2) were used to screen the four
databases. After rejecting hits with a MW e800 Da, unusual
bonds, or several fragments, the ACD database produced 63 hits
using query phar4 and 114 hits using phar31 and phar32.
Likewise, the NCI database yielded 42 and 210 hits for the four-
and three-point queries, respectively. No hits were obtained from
the other two remaining databases.
Although molecules with MW greater than 500 Da are not
usually regarded as drug-like compounds, our own experience
indicates that sometimes molecules with MW between 500 and
800 Da properly fulﬁll the pharmacophore requirements and
show a good interaction proﬁle. However, they also have some
noninteracting groups which are solvent exposed. Deletions of
these groups generate small molecules that retain interaction
points and that may exist in other databases or that can be
synthesized in further studies. So, in order to cover these
possibilities, we decided to include compounds having a
MW e800 Da.
In a further step, the in-house pharmacophore-based docking
program DockDyn, described in the Docking Studies Section,
was used to ﬁlter compounds for further testing. From the 429
initial hits docked into the binding site of Bcl-xL, only those with a
RMSD <2.5 Å for the four-point query and <1.5 Å for the three-
point query, respectively, were considered for in vitro testing.
Accordingly, the ﬁnal set consisted of 29 compounds, 20 of them
from the NCI database and 9 from the ACD database. However,
two of the 20 compounds found in the NCI list were the same
molecule, and one of them appeared in both databases. So,
the ﬁnal set was reduced to 27 compounds. Of them, the 19 from
the NCI were requested but ﬁnally only seven were received.
Likewise eight ACD’s compounds were purchased.
The binding aﬃnity of the acquired 15 compounds to Bcl-xL
was determined in vitro using a competitive ﬂuorescence polariza-
tion assay. For this assay, 5-carboxyﬂuorecein was coupled to the
N-terminus of the Bak peptide (CF-Bak(BH3)). This ﬂuorescent
Figure 3. IC50 values for each of the tested compounds. These values,
obtained by ﬂuorescence polarization assays, represent the mean ( SD
of three diﬀerent measurements.
Figure 4. Best docking pose obtained for the UBQF14 compound
bound to Bcl-xL using: (a) the DockDyn program (phar32), (b) the
Glide program (pose1), and (c) after 6 ns of MD using (b) structure as
starting point.
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analogue binds to Bcl-xL with high aﬃnity (dissociation constant
KD = 2 μM). Nonﬂuorescent Bak(BH3) peptide
24 was used as
positive control. The binding aﬃnity of each compound for Bcl-xL
was evaluated by determining its ability to compete with CF-
Bak(BH3) for Bcl-xL binding. Initially, all compounds were
analyzed at a ﬁxed concentration, and themost activewere selected
for subsequent analysis and IC50 values determination. Among the
15 compounds tested, three of them were able to displace CF-
Bak(BH3) from Bcl-xL (See Figure 3 and Figure S1, Supporting
Information). Compounds UBQF-14 and UBQF-17 showed the
most potent activity with IC50 values of 8 μM (doseresponse
graphs for these compounds are included in Figure S2, Supporting
Information).
To overcome the problems related to the target promiscuity of
UBQF-14 and UBQF-17, they were tested in a completely
unrelated enzymatic inhibition assay as previously described.55
The ability of these compounds to inhibit theβ-lactamase activity
was measured at diﬀerent concentrations (see Figure S3, Sup-
porting Information). In the case of UBQF-17, no inhibition was
observed at concentrations 10-fold higher than the IC50 of the
compound. The compound UBQF-14 did not show relevant
β-lactamase inhibition activity at concentrations up to 25 μM,
but it clearly increased at higher concentrations. However, since
the IC50 calculated for UBQF-14 is 7 μM, the possible unspeciﬁc
inhibition may not aﬀect the results observed for Bcl-xL.
In order to elucidate the most probable binding mode of
UBQF-14 and UBQF-17 compounds to Bcl-xL for further
optimization, docking studies using the Glide Induced Fit
Docking Protocol (IFD) and the DockDyn procedures were
performed. Thus, in order to compare both procedures and to
avoid unreasonable ligand conformations, the best poses gene-
rated by each program were selected for MD reﬁnement and
further rescoring using the MM-PB/GBSA approach.
For this purpose, poses generated with the Glide IFD protocol
were classiﬁed according to the binding pattern. Only the top-
ranked pose of the most populated binding modes (3 for
UBQF14 and 11 for UBQF17) were selected. In the case of
the DockDyn program, selection of the best poses was based on
the RMSD value between their pharmacophoric groups and the
pharmacophore query for which they have been proposed. For
Figure 5. Best docking pose obtained for the UBQF17 compound bound to Bcl-xL using: (a) the DockDyn program (phar4), (b) the DockDyn
program (phar32), (c) the DockDyn program (phar31), and (d) the Glide program (pose10) after 6 ns of MD.
Table 1. Mean Values of the MM-PBSA and MM-GBSA
Binding Free Energy Terms in kcal/mol for the Bcl-xL/
UBQF14 and Bcl-xL/UBQF17 Complexes for the
Last 2 ns of the MD Trajectoriesa
compound method ΔGtotal ΔGvdW ΔGelec ΔGnp ΔGsolv,elec
UBQF14 PB 33.8
50.1 113.7
6.5 90.8
GB 31.8 5.1 90.2
UBQF17 PB 47.6
67.4 30.4
8.8 1.8
GB 44.3 7.3 0.0
aΔGvdW and ΔGelec represent the nonbonded electrostatic
(Coulombic) and van der Waals (Lennard-Jones) MM interaction
energy. ΔGnp and ΔGsolv,elec are the nonpolar and electrostatic compo-
nents of the solvation free energy, respectively.
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this selection, only poses having a RMSD e2.5 Å for phar4 and
e1.5 Å for phar31 and phar32 were considered. So, for UBQF14,
the DockDyn protocol generated a pose with a RMSD = 0.88 Å
using the three-point pharmacophore query phar32. No poses
were obtained below the predeﬁned RMSD value for the other
two remaining queries. For the UBQF17 compound, all three
pharmacophore queries generated poses with acceptable RMSD
values of 0.63, 0.30, and 0.41 Å for phar4, phar31, and phar32,
respectively. Accordingly, a total of 19 complexes (four forUBQF14
and 15 for UBQF19) were considered for further analysis.
Figure 4a shows the pose generated using DockDyn for
UBQF14. As can be seen, the aromatic rings of this compound
ﬁt into the hydrophobic pockets of the Bcl-xL protein. One of its
sulfonic acid groups is oriented toward the positive surface formed
by the residues Arg100, Arg103, and Arg204, fulﬁlling the pharma-
cophore requirement HBA2 (Figure 2). The other sulfonic acid
group, oriented to Arg132, is allocated far away from the Arg139 due
to the absence of the HBA1 pharmacophore requirement.
Comparison between the UBQF14 DockDyn pose and the
top ranked produced by Glide IFD (Figure 4b) reveals that they are
clearly diﬀerent, although the last one is closer to that obtained with
DockDyn using phar31 as pharmacophore query. However, the
RMSD cutoﬀs imposed in order to accept or discard poses generated
by the DockDyn protocol prevented us from including this phar31-
derived pose in the set of solutions produced by this program.
Figure 5 shows the three poses obtained for the UBQF17
compound by means of the DockDyn program using phar4,
phar32, and phar31 as pharmacophore queries. As can be seen,
poses derived from phar4 and phar32 are very similar (Figures 5a
and b), whereas major diﬀerences are observed for the phar31
derived pose (Figure 5c).
As has been previously commented, a total of 19 complexes
formed by the Bcl-xL protein and the best poses generated for the
UBQF14 and UBQF17 compounds by the DockDyn and Glide
IFD programs were rescored using the MM-PBSA and MM-
GBSA approaches. For UBQF14, the best binding free energy
value was obtained by either of these approaches for the complex
formed by the Bcl-xL protein and the top-ranked pose generated
by the Glide IFD program. Similarly, both approaches coincided
in identifying the complex formed by Bcl-xL and the tenth
energy-ranked pose of UBQF17 generated by Glide IFD as the
most stable. These complexes, considered as the most probable
binding modes of UBQF14 and UBQF17 to Bcl-xL, are shown in
Figures 4c and 5d.
Table 1 shows the contributions of the diﬀerent energy terms
to the MM-PBSA and MM-GBSA binding free energy. As can be
seen, in both approaches, the electrostatic component of the
solvation free energy makes the largest contribution to the
binding of UBQF14 to Bcl-xL. Conversely, the binding of
UBQF17 to this protein is clearly dominated by the van der
Waals interaction. Moreover, for both compounds, the electro-
static term is unfavorable, whereas the nonpolar solvation term
contributes only slightly favorably to the binding.
In a further step,MM-GBSA decomposition approach of these
complexes was performed in order to identify residues of the Bcl-
xL protein that make signiﬁcant contributions to the binding free
energy associated to the complex formation (hot spot). In the
present work, it was considered as a hot spot if any residue
contributes more than 1.0 kcal/mol to the binding free energy of
the complex.
Figure 6 shows the residues of Bcl-xL found tomake a signiﬁcant
contribution to ligand binding. In both complexes, residues of the
protein that have the largest contribution to ligand binding are the
arginine residues lining the binding site. However, their contribu-
tion varies from one complex to the other one. In the Bcl-xL/
UBQF14 complex, Arg139 (located at the HBA1 zone) and Arg100
Figure 6. Residues of Bcl-xL that contribute more than 1.0 kcal/mol to the binding free energy of the complexes.
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(located at the HBA2 zone) are the most contributing residues to
the binding free energy of the complex. In contrast, their con-
tribution to the UBQF17 binding is lower compared to that
observed for the residues Arg100, Arg103, Arg204 (located at the
HBA2 zone), and Arg209.
With respect to the hydrophobic interactions, all residues with
signiﬁcant contribution to the free binding energy belong to one of
the four hydrophobic pockets (referred to as h1h4) located on the
binding site surface of the Bcl-xL protein. Speciﬁcally, UBQF14 spans
over h2 (residues Phe105 and Leu130), h3 (including residues Phe97,
Arg100, Tyr101, and Ala142), and h4 (residue Tyr195) pockets. In
contrast, UBQF17 only occupies h2 (with residues Leu130 and
Phe146) and h3 (residues Phe97, Arg100, Tyr101, and Ala142) pockets.
Finally, it is interesting to stress that the two compounds show
similar binding patterns than the BH3 domains to anti-apoptotic
proteins,35 although in this case, only three of the four hydro-
phobic sites are occupied by each antagonist due to their reduced
size in comparison with BH3 peptides. This suggests that any
modiﬁcation of these compounds oriented to ﬁll the unoccupied
pocket could improve the aﬃnity of these compounds for Bcl-xL.
All necessary structures to reproduce Figures 2, 4, and 5
(obtained using the software Pymol version 0.99rc6) are pro-
vided as pdb ﬁles in the Supporting Information.
’CONCLUSIONS
In the present work, a pharmacophore-based strategy was used
for the discovery of small molecule antagonists of the anti-apoptotic
protein Bcl-xL. The pharmacophore was derived fromMD studies of
the Bcl-xL/X(16BH3) complexes, were X represents a BH3 hexade-
capeptide of the pro-apoptotic proteins Bak, Bax, Bid, and Hrk and
was not only used for virtual screening but also for site-directed
docking. This strategy allowed the identiﬁcation of 29 hits as Bcl-xL
antagonist candidates. Fifteen of them were acquired and assayed to
assess their ability to disrupt the Bcl-xL/Bak(BH3) complex. Two of
these compounds, UBQF14 and UBQF17, were able to avoid the
Bcl-xL/Bak(BH3) interaction in vitro at the micromolar range. In
order to characterize their binding mode, docking studies were
performed.MD simulations followed byMM-PBSA andMM-GBSA
binding free energy calculations were used as tools to reﬁne and
rescore the docked structures. Bcl-xL/UBQF14 and Bcl-xL/UBQF17
complexes having the best binding free energy values were chosen as
those containing the most probable binding mode of these com-
pounds. In order to indentify which residues of the Bcl-xL protein
make the largest contribution to their binding, a MM-GBSA decom-
position approach was performed on each one of the two obtained
complexes. Hot spots reported by previous studies analyzing
Bcl-xL/BH3-only protein complexes completely agree with those
found in theMM-GBSA analysis. Taken together, these results clearly
demonstrate the success of the strategy developed in the presentwork
as a tool for drug discovery, appearing as a less-expensive and reliable
alternative to high-throughput experimental screening.
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